Report Detail

Pharmaceuticals PR001 - Emerging Insight and Market Forecast - 2030

  • RnM4285705
  • |
  • 12 February, 2021
  • |
  • Global
  • |
  • 30 Pages
  • |
  • DelveInsight
  • |
  • Pharmaceuticals

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

    4. Analyst Views

      5. Market Competitors

        6. Other Emerging Therapies

          7. Appendix

            8. Report Purchase Options

            “PR001 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Gaucher disease in 7 Major Markets. A detailed picture of the PR001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

            Overview
            PR001 is an investigational single-dose gene therapy for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease. PR001 is a gene-replacement therapy that uses adeno-associated virus 9 to deliver a functional copy of the GBA1 gene to the brain. The therapy comprises a one-time injection into the cerebrospinal fluid in the cisterna magna at the base of the brain. The USFDA has granted Fast Track designation for PR001 for the treatment of neuronopathic Gaucher disease. It has also granted Orphan Drug designation for PR001 for the treatment of patients with Gaucher disease, and Rare Pediatric Disease designation for the treatment of neuronopathic Gaucher disease.

            Scope of the report
            The report provides insights into:
            • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
            • Elaborated details on regulatory milestones and other development activities have been provided in this report.
            • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
            • The report also covers the patents information with expiry timeline around PR001.
            • The report contains forecasted sales for PR001 till 2030.
            • Comprehensive coverage of the early-stage emerging therapies (Phase I/II) for Gaucher's disease.
            • The report also features the SWOT analysis with analyst insights and key findings of PR001.

            Methodology
            The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

            PR001 Analytical Perspective by DelveInsight
            • In-depth PR001 Market Assessment
            This report provides a detailed market assessment of PR001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

            • PR001 Clinical Assessment
            The report provides the clinical trials information of PR001 covering trial interventions, trial conditions, trial status, start and completion dates.

            Report highlights
            • In the coming years, the market scenario for Gaucher's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
            • The companies and academics are working to assess challenges and seek opportunities that could influence PR001 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
            • Other emerging products for Gaucher's disease are giving market competition to PR001 and launch of early-stage emerging therapies in the near future will significantly impact the market.
            • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of PR001.
            • Our in-depth analysis of the forecasted sales data of PR001 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PR001.

            Key Questions
            • Which company is developing PR001 along with the phase of the clinical study?
            • What is the technology utilized in the development of PR001?
            • What is the product type, route of administration and mechanism of action of PR001?
            • What is the clinical trial status of the study and study completion date?
            • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PR001 development?
            • What are the key designations that have been granted to PR001?
            • What is the forecasted market scenario of PR001?
            • What is the history of PR001 and what is its future?
            • What is the forecasted sales of PR001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
            • What are the other emerging products available and how these are giving competition to PR001?
            • Which are the late-stage emerging therapies under development for the treatment of the Gaucher disease?


            Summary:
            Get latest Market Research Reports on PR001. Industry analysis & Market Report on PR001 is a syndicated market report, published as PR001 - Emerging Insight and Market Forecast - 2030. It is complete Research Study and Industry Analysis of PR001 market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

            Last updated on

            REPORT YOU MIGHT BE INTERESTED

            Purchase this Report

            $3,250.00
            $6,500.00
            $9,750.00
            2,347.26
            4,694.52
            7,041.78
            2,734.26
            5,468.53
            8,202.79
            353,492.75
            706,985.50
            1,060,478.25
            238,351.43
            476,702.85
            715,054.27
            Credit card Logo

            Related Reports


            Reason to Buy

            Request for Sample of this report